Mitophagy in cardiovascular disease.
Atherosclerosis
Cardiac hypertrophy
Heart failure
Hypertension
Ischemiareperfusion injury
Mitophagy
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
24
02
2020
revised:
27
04
2020
accepted:
28
04
2020
pubmed:
4
5
2020
medline:
14
1
2021
entrez:
4
5
2020
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) leads to high morbidity and mortality rates worldwide. Accumulating evidence has revealed that mitochondria dysfunction is implicated in CVD, such as atherosclerosis (AS), hypertension, myocardial ischemia-reperfusion (MI/R) injury, myocardial infarction (MI), cardiac hypertrophy, heart failure (HF), dilated cardiomyopathy (DCM) and so on. Mitophagy is a mitochondrial quality control mechanism that eliminates damaged or superfluous mitochondria to maintain cardiac function in response to various stress and cardiac disease conditions. This article reviews the latest findings regarding the mechanistic, functional, and potential role of mitophagy in the pathogenesis of CVD. Moreover, various drugs can target mitophagy activity during CVD progression. Thus, the modulation of the mitophagy pathway provides a potential therapeutic strategy for CVD management.
Identifiants
pubmed: 32360616
pii: S0009-8981(20)30192-3
doi: 10.1016/j.cca.2020.04.033
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
210-218Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.